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ABSTRACT
Background Mortality in people with and without
diabetes often exhibits marked social patterning, risk of
death being greater in deprived groups. This may reﬂect
deprivation-related differences in comorbid disease
(conditions additional to diabetes itself ). This study
sought to determine whether the social patterning of
mortality in a population with type 2 diabetes mellitus
(T2DM) is explained by differential comorbidity.
Methods Hospital records for 70 197 men and 56 451
women diagnosed with T2DM at 25 years of age and
above in Scotland during the period 2004–2011 were
used to construct comorbidity histories. Sex-speciﬁc
logistic models were ﬁtted to predict mortality at 1 year
after diagnosis with T2DM, predicted initially by age and
socioeconomic status (SES) then extended to incorporate
in turn 5 representations of comorbidity (including the
Charlson Index). The capacity of comorbidity to explain
social mortality gradients was assessed by observing the
change in regression coefﬁcients for SES following the
addition of comorbidity.
Results After adjustment for age and Charlson Index,
the OR for the contrast between the least deprived and
most deprived quintiles of SES for men was 0.79 (95%
CI 0.67 to 0.94). For women, the OR was 0.81 (0.67 to
0.97). Similar results were obtained for the 4 other
comorbidity measures used.
Conclusions The social patterning of mortality in
people with T2DM is not fully explained by differing
levels of comorbid disease additional to T2DM itself.
Other dimensions of deprivation are implicated in the
elevated death rates observed in deprived groups of
people with T2DM.
INTRODUCTION
Mortality in people with diabetes is often elevated
relative to non-diabetic populations; a recent
meta-analysis concluded that mortality in diabetic
populations is increased approximately twofold
relative to those without diabetes.1 Death from car-
diovascular disease is a major contributor to this
excess mortality.2 3 Within diabetic populations,
mortality often exhibits social patterning, all-cause
mortality risk being raised in more deprived
groups.4–6 Because many clinical conditions in add-
ition to diabetes demonstrate social patterning, the
apparent inﬂuence of socioeconomic status (SES)
on mortality in diabetic groups may be wholly or
partly explained by different burdens of comorbid-
ity (diseases additional to diabetes itself ). Assessing
the role of comorbidity in the association between
SES and mortality is challenging, not least because
no generally recognised standard method of meas-
uring comorbidity exists. Representations of
comorbidity developed by Charlson et al7 and
Elixhauser et al8 have been used in a variety of con-
texts. Other approaches to measuring comorbidity
include those based on the number of hospital
bed-days accrued by the patient,9 or the total
number of distinct drug classes recorded in the
individual’s medication history.10 A number of
studies have compared the respective performances
of multiple comorbidity measures in predicting
mortality,11–13 but no measure has emerged as deli-
vering an unequivocal ‘best’ predictive perform-
ance. Consequently, when attempting to determine
whether the social mortality gradient observed in
people with diabetes is explained by comorbidity,
multiple representations of the latter must be
assessed to ensure that the ﬁndings are not unduly
inﬂuenced by some peculiarity of an individual
comorbidity index. The present study sought to
determine whether comorbidity (measured in ﬁve
different ways) explained social mortality differen-
tials in a population with type 2 diabetes mellitus
(T2DM).
METHODS
Data sources
Data for people diagnosed with T2DM in Scotland
were obtained from the Scottish Care
Information-Diabetes Collaboration (SCI-DC) data
set,14 which stores clinical and demographic data
on almost all patients with diabetes in Scotland.
The study was based on an extract of SCI-DC data
performed in 2011, and was restricted to people
diagnosed with T2DM at 25 years of age and
above during the period from 1 January 2004 to
18 May 2011. The study end date was deﬁned as
18 May 2012, ensuring that 1 year of follow-up
time was available for all patients. The SCI-DC
data were linked to hospital discharge records,
national death records and prescribing data by the
Information Services Division (ISD) of National
Health Service (NHS) National Services Scotland
(NHSNSS). Generation of the linked data set was
approved by the responsible ethics committee,
Caldicott guardians and the NHSNSS Privacy
Application Committee (application no. 33/11). All
data were anonymised before release to the
researchers.
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Comorbidity and SES
Hospital discharge records covering the period 5 years prior to
diagnosis with T2DM were used to construct four different
measures of comorbidity. Scottish hospital records include six
diagnosis ﬁelds (one holding the clinical condition mainly
responsible for admission, the remaining ﬁve storing details of
conditions which coexist or develop during the episode of
healthcare and affect the management of the patient). The pres-
ence of a relevant clinical condition in any of these six diagnosis
ﬁelds was accepted in constructing the comorbidity measures
used in this study. For the period under investigation, all condi-
tions were coded in accordance with the International
Classiﬁcation of Diseases, V.10 (ICD10).15 The ﬁrst comorbidity
measure derived from hospital records was the Charlson
Comorbidity Index (CCI)7 as reﬁned by Romano et al.16 This is
a single-number (integer) quantity with possible values ranging
from 0 (no comorbidity) to 29 (maximum comorbidity).
Mapping of the original Charlson groups to ICD10 codes fol-
lowed the scheme used by ISD to construct hospital standar-
dised mortality ratios.17 The second representation of
comorbidity was a set of binary indicators marking the presence
or absence of 30 speciﬁc disease groups deﬁned by Elixhauser
et al.8 In constructing these indicators, the mapping of
Elixhauser’s original comorbidities to ICD10 provided by Quan
et al18 was used. The third comorbidity measure constructed
was the number of hospital in-patient bed-days accrued by each
person during the 5-year period prior to diagnosis with T2DM.
To provide a fourth measure, a group of binary indicators
marking the presence or absence of 25 disease groups deﬁned
by ISD to guide coding of comorbid clinical conditions on
Scottish hospital discharge records19 was created. These groups
were developed by condensing 1127 ICD10 codes from 232
categories, and represent conditions deemed to have substantial
prognostic signiﬁcance. A ﬁfth comorbidity measure was derived
from patients’ prescribing histories, namely a count of the
number of unique drug classes (British National Formulary
(BNF) codes20) present in the database of medication prescribed
in primary care during the 5 years before T2DM diagnosis.
The measure of SES used was the Scottish Index of Multiple
Deprivation (SIMD).21 This is a small area-based ranked
measure which combines 38 indicators of deprivation across
seven different conceptual domains. Development of SIMD is
sponsored by the Scottish Government via a rigorous academic
process as the standard method of assessing deprivation in
Scotland. It is the only measure of SES for which up-to-date
national data covering the whole Scottish population are rou-
tinely available, and was thus the natural choice for this
population-based study. SIMD is a ranked (as distinct from an
absolute) measure and, for this reason, cannot be represented in
analysis as a numeric quantity; rather, it must be included as
some kind of categorical variable. For the purposes of this inves-
tigation, rankings of the 6505 geographical areas recorded in
SIMD were expressed as quintiles (the ﬁrst and ﬁfth quintiles
representing the most and least deprived groups in the popula-
tion, respectively). This reduction to a ﬁve-way classiﬁcation
scheme offered a good compromise between sacriﬁcing too
much information (too few levels) and ending up with undesir-
ably small numbers in some strata (too many levels).
Statistical analysis
An initial logistic regression model was ﬁtted in which mortality
at 1 year after T2DM diagnosis (ie, vital status dead vs alive)
was predicted only by age at diagnosis (represented by a
restricted cubic spline function to accommodate non-linear
effects of age on mortality) and by SES (binary indicators
marking quintiles 2–5 of SIMD, with the most deprived quintile
1 deﬁned as the reference category). Separate models were ﬁtted
for each sex, to accommodate potential sex-related differences
in the prognostic implications of some disease groups (notably
cancer, which includes malignancies at sex-speciﬁc sites eg, pros-
tate, cervix). From these initial models, the parameter estimates
representing the effect of SIMD quintile on 1-year mortality
were noted. Modelling was performed using a combination of
R software (V.3.0.3; the ‘lrm’ function in package ‘rms’) and
SAS (V.9.4; the ‘LOGISTIC’ procedure). The models were then
extended by adding each of the ﬁve comorbidity measures in
turn (only a single measure being included at any one time), and
recording the amended estimates for the effect of SIMD on
mortality. In ﬁtting the models with comorbidity, certain manip-
ulations of the comorbidity measures were performed in the
interests of analytic practicality; these are now summarised for
each measure involved. First, the distribution of the CCI was
found to be heavily skewed, with high proportions of zero
values, that is, no comorbidity (men: 80.5%; women: 80.4%).
Reﬂecting this, the original scores on the CCI were reduced to a
four-way categorical scheme: 0, 1, 2–3, and 4 and above (con-
ceptualised as representing respectively zero, mild, moderate
and high levels of comorbidity). Values of the CCI discretised in
this way were found to exhibit material interactions with age, so
terms representing the interaction of CCI with the spline com-
ponents of age were included in the models. A second set of
manipulations was motivated by problems of non-convergence
experienced when ﬁtting the logistic model which featured the
Elixhauser comorbidity set. These difﬁculties were attributable
to the indicator marking the presence of AIDS, which exhibited
extremely low prevalence (<0.01%). Convergence difﬁculties
also arose in connection with a small number of other ‘rare’
Elixhauser comorbidities, for example, blood loss anaemia
(prevalence <0.05% in men). To permit successful modelling of
the Elixhauser comorbidities, the indicator representing AIDS
was omitted from the models: this was justiﬁed on the grounds
that because the condition was so rare in the cohort, its effect
on overall mortality was likely to be extremely small. To permit
meaningful parameter estimates to be obtained for other
sparsely represented conditions in the Elixhauser set, Firth’s
bias-reducing penalised likelihood method22 was adopted. A
third series of modiﬁcations to the original comorbidity
measure values was applied in connection with in-patient
bed-days. The distribution of this was found to be heavily
skewed with a small number of extremely large values, and was
therefore reduced for analysis to the four-way ordinal classiﬁca-
tion used by Parks et al9: 0, 1–4, 5–10, and 11 and above. A
fourth manipulation of comorbidity values was performed when
ﬁtting models which included the ISD comorbidity suite: here,
the indicator representing the presence of AIDS/HIV was again
omitted in the interests of permitting the logistic model to con-
verge. Finally, values for the prescribing-based comorbidity
measure (number of distinct BNF codes) showed a non-linear
relationship with the outcome (1-year mortality), so this
measure was represented in analysis as a restricted cubic spline
function. In summary, the comorbidity measures as represented
in the models consisted of two ordinal schemes (CCI and
number of bed-days), two groups of condition-speciﬁc binary
indicators (Elixhauser with 29 retained indicators and the ISD
scheme with 24 retained indicators) and one continuous (more
correctly, non-negative integer) quantity (number of unique
BNF codes), represented as a spline function.
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RESULTS
From an initial candidate cohort of 126 725 (representing all
patients diagnosed with T2DM in Scotland at ages 25 and
above during the study period), 77 (0.06%) were excluded
because date of death was uncertain. The cohort retained for
analysis consisted of 70 197 men and 56 451 women.
Characteristics of the study cohort are summarised in table 1.
The prevalence of individual comorbidities in the two
indicator-based comorbidity measures (Elixhauser and the ISD
comorbidity scheme) is shown in table 2. Summary values for
the two ordinal comorbidity schemes (CCI and number of
bed-days) and the single continuous quantity (number of unique
BNF codes) are given in table 3.
Figure 1 shows the effect of SES (quintile of SIMD) on 1-year
mortality in men, corresponding estimates for women being pre-
sented in ﬁgure 2. These charts illustrate the OR estimate for
each quintile of SIMD (relative to Q1, the most deprived quin-
tile) as a predictor of 1-year mortality, adjusted for age only and
for age plus each of the ﬁve comorbidity measures. For men,
the OR estimate for the contrast between SIMD quintile 5 (least
deprived) and quintile 1 (most deprived) was 0.70 (95% CI
0.59 to 0.83) before adjustment for comorbidity. After adjust-
ment for comorbidity, corresponding values were 0.79 (0.67 to
0.94) for the CCI; 0.77 (0.65 to 0.92) for the Elixhauser indica-
tors; 0.77 (0.65 to 0.91) for in-patient bed-days; 0.79 (0.66 to
0.94) for the ISD comorbidity set; and 0.75 (0.63 to 0.88) for
number of unique drug classes. For women, corresponding esti-
mates were 0.74 (0.62 to 0.89) for no comorbidity; 0.81 (0.67
to 0.97) for the CCI; 0.77 (0.64 to 0.93) for the Elixhauser
indicators; 0.81 (0.68 to 0.97) for in-patient bed-days; 0.77
(0.64 to 0.93) for the ISD comorbidity set; and 0.81 (0.67 to
0.97) for number of unique drug classes.
DISCUSSION
The pervasive nature of SES-related health inequalities (includ-
ing mortality gradients) is now universally accepted, although
debate continues as to the explanation(s) for this ubiquitous
phenomenon.23 Because differential mortality by SES is
observed in many societies, populations and contexts, it is argu-
ably not surprising that such an association has also been
recorded in people with diabetes. However, although ‘there are
important indicators of social deprivation which predict mortal-
ity over and above diabetic health status itself ’ (ref. 4, p.205),
the present study is believed to be the ﬁrst to investigate
Table 1 Characteristics of study cohort
Men (n=70 197) Women (n=56 451)
Age at diabetes diagnosis, years
(mean (SD))
60.5 (12.3) 63.6 (13.0)
SIMD quintile: n (%) in
Q1 (most deprived) 15 567 (22.2) 13 851 (24.5)
Q2 15 474 (22.0) 13 275 (23.5)
Q3 14 374 (20.5) 11 432 (20.3)
Q4 13 536 (19.3) 10 042 (17.8)
Q5 (least deprived) 11 246 (16.0) 7851 (13.9)
n (%) dead within 1 year after diabetes diagnosis in
SIMD Q1 371 (2.4) 363 (2.6)
Q2 393 (2.5) 319 (2.4)
Q3 327 (2.3) 282 (2.5)
Q4 304 (2.2) 271 (2.7)
Q5 231 (2.1) 198 (2.5)
Table 2 Prevalence of individual comorbidities represented in the
Elixhauser and Information Services Division (ISD) comorbidity
schemes
Elixhauser
Men Women
Comorbidity n Per cent N Per cent
Congestive heart failure 2289 3.26 1451 2.57
Cardiac arrhythmias 3554 5.06 2875 5.09
Valvular disease 898 1.28 841 1.49
Pulmonary circulation disorders 410 0.58 423 0.75
Peripheral vascular disorders 1564 2.23 806 1.43
Hypertension 7843 11.17 7410 13.13
Paralysis 314 0.45 228 0.40
Other neurological disorders 930 1.32 821 1.45
Chronic pulmonary disease 3194 4.55 3568 6.32
Diabetes, uncomplicated 2593 3.69 2021 3.58
Diabetes, complicated 71 0.10 41 0.07
Hypothyroidism 308 0.44 1330 2.36
Renal failure 782 1.11 580 1.03
Liver disease 909 1.29 617 1.09
Peptic ulcer excluding bleeding 611 0.87 452 0.80
AIDS* 6 0.01 1 0.00
Lymphoma 183 0.26 100 0.18
Metastatic cancer 270 0.38 391 0.69
Solid tumour without metastasis 1680 2.39 1621 2.87
Rheumatoid arthritis/collagen vascular
disease
384 0.55 727 1.29
Coagulopathy 221 0.31 166 0.29
Obesity 1307 1.86 1353 2.40
Weight loss 250 0.36 242 0.43
Fluid and electrolyte disorders 548 0.78 656 1.16
Blood loss anaemia 33 0.05 49 0.09
Deficiency anaemia 537 0.76 773 1.37
Alcohol abuse 873 1.24 395 0.70
Drug abuse 101 0.14 46 0.08
Psychoses 168 0.24 128 0.23
Depression 511 0.73 847 1.50
ISD
Solid metastases 257 0.4 385 0.7
Chronic pulmonary disorders 3162 4.5 3541 6.3
Heart failure/cardiomyopathy 2568 3.7 1663 2.9
Malignancies 2593 3.7 2464 4.4
Pulmonary circulation disorders 141 0.2 163 0.3
Peripheral vascular disease 1426 2.0 783 1.4
AIDS/HIV* 15 0.0 5 0.0
Cerebrovascular disease 968 1.4 783 1.4
Ischaemic heart disease 7870 11.2 4748 8.4
Diabetes 2664 3.8 2062 3.7
Liver disease 935 1.3 655 1.2
Hypertension, complicated 134 0.2 141 0.2
Cardiac arrhythmias 3538 5.0 2819 5.0
Dementia 206 0.3 354 0.6
Obesity 1307 1.9 1353 2.4
Valvular heart disease 787 1.1 765 1.4
Coagulopathy 227 0.3 170 0.3
Drug/alcohol abuse 2532 3.6 1104 2.0
Hemiplegia/paraplegia 334 0.5 243 0.4
Other neurological disorders 568 0.8 538 1.0
Renal disease 782 1.1 627 1.1
Continued
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whether social mortality differentials in a diabetic population
actually reﬂect variation in the overall burden of disease across
socioeconomic strata. The ﬁndings of this study suggest that
even after adjustment has been made for variation in the burden
of non-diabetic disease, a residual effect of SES remains signiﬁ-
cantly predictive of mortality. The OR estimates representing
the association between SIMD quintile and death are modestly
attenuated when further adjustment is made for measures of
comorbidity based on hospital records or primary care prescrib-
ing (ﬁgures 1 and 2). However, the basic structure of the associ-
ation (loosely, a monotonic gradient in men and a contrast of
‘most deprived vs others’ in women) is broadly preserved after
the introduction of comorbidity. This holds true irrespective of
which measure of comorbidity derived from routine data is
used. In passing, it merits highlighting that the between-sex dif-
ference in the pattern of association between SES and mortality
evident in ﬁgures 1 and 2 is not consistent with the ﬁndings of
Roper et al,5 who observed a gradient effect for both sexes.
On this basis of the study reported here, it may reasonably be
concluded that SES-related mortality differences in a population
with T2DM are not due to more afﬂuent groups being ‘less
sick’: some other dimensions of SES are implicated. Accepted
inﬂuences on the social patterning of health and mortality
include material deprivation, childhood social development,
social exclusion, occupational status and security, educational
attainment, and housing environment and tenure.24 25 It is of
course impossible to determine which (if any) of these may be
contributing to the residual effect of SES (ie, that remaining
after adjustment for comorbidity) in the population studied
here.
Table 2 Continued
Elixhauser
Men Women
Comorbidity n Per cent N Per cent
Nutritional anaemia 560 0.8 809 1.4
Hypertension, uncomplicated 7771 11.1 7341 13.0
Psychoses 226 0.3 206 0.4
Malnutrition/weight loss 251 0.4 224 0.4
*Condition not included in analysis.
Table 3 Summary values for CCI, number of in-patient bed-days,
and number of unique BNF codes in patient’s medication history
Men Women
CCI (n/% of total)
0 56 537/80.5 45 383/80.4
1 7321/10.4 5983/10.6
2–3 5186/7.4 4154/7.4
4+ 1153/1.6 931/1.6
Number of in-patient bed-days (n/% of total)
0 35 359/50.4 26 305/46.6
1–4 16 400/23.4 13 208/23.4
5–10 7709/11.0 6770/12.0
≥11 10 729/15.3 10 168/18.0
Number of unique BNF codes
Minimum/maximum 0/67 0/67
Mean/SD 9.4/7.4 13.2/9.0
Median/IQR 8/9 12/11
n/% of zero values (no comorbidity) 5861/8.3 3109/5.5
BNF, British National Formulary; CCI, Charlson Comorbidity Index.
Figure 1 OR estimates for the association between socioeconomic
status (Scottish Index of Multiple Deprivation (SIMD) quintile) and
1-year mortality in men, adjusted for age only (no comorbidity) and for
age plus ﬁve representations of comorbidity. Estimates are expressed
relative to reference category SIMD quintile 1 (most deprived). Dashed
horizontal line marks OR of unity (‘no association’).
Figure 2 OR estimates for the association between socioeconomic
status (Scottish Index of Multiple Deprivation (SIMD) quintile) and
1-year mortality in women, adjusted for age only (no comorbidity) and
for age plus ﬁve representations of comorbidity. Estimates are
expressed relative to reference category SIMD quintile 1 (most
deprived). Dashed horizontal line marks OR of unity (‘no association’).
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Strengths of this study are threefold. First, it is population-
based: the data include almost all eligible individuals with dia-
betes in the entire Scottish population during the period
covered. Consequently, many of the biases potentially intro-
duced when research is based on selected samples (eg, patients
from a speciﬁc group of hospitals) are avoided. A second
strength of this investigation is the adoption of multiple
methods of measuring comorbidity. As discussed earlier, there is
no ‘gold standard’ for quantifying comorbidity (though the CCI
has arguably become something of a de facto standard in this
ﬁeld), so it is advisable in a study such as the present to include
on a comparative basis several different representations of
comorbid disease. This provides protection against the ﬁndings
reﬂecting the peculiarities of a speciﬁc comorbidity index.
A third strength is the nature of the representation of SES used
in the study. The SIMD was designed to provide a multifaceted
portrayal of deprivation status, and thus arguably provides a
better approximation to the individual’s ‘true’ position in the
social and economic hierarchy than single-dimension measures
such as income or educational attainment.
Several limitations of the study are acknowledged. First,
although ﬁve different approaches to representing the abstract
concept of ‘comorbidity’ have been compared, none of these can
claim to be truly comprehensive or of unimpeachable accuracy.
Four of the measures used are based on hospital discharge
records, and thus cannot reﬂect clinical conditions identiﬁed or
treated in primary care. For example, the prevalence of the
Elixhauser condition ‘obesity’ derived from hospital data (table 2)
is many times lower than the authoritative prevalence values
reported in the Scottish Diabetes Survey.26 Moreover, inconsisten-
cies across hospitals or inaccuracies may arise in the coding of
conditions. To illustrate, table 2 reveals instances of reported dia-
betes in the study data even though the comorbidity measures are
derived from hospital episodes recorded prior to formal diagnosis
of diabetes. While the ﬁfth measure is constructed from medica-
tion records rather than hospital data, it also embodies a number
of weaknesses. For example, it provides no indication of the
intensity of drug treatment (ie, frequency and dosage), and obvi-
ously cannot reﬂect the patient’s compliance with her/his medica-
tion regime (which might be expected to inﬂuence the outcome
associated with the treatment). A second limitation of the study
relates to the nature of the measure of SES used, that is, SIMD.
As outlined above, this attempts to reﬂect the multidimensional
nature of deprivation, but the use of an area-based measure to
represent the characteristics of an individual leads to an obvious
inferential pitfall: not all deprived people live in deprived areas,
and not all residents of a deprived area are necessarily deprived.
However, the 6505 areas used by SIMD (data zones) are rela-
tively small in population terms, the average number of residents
being c. 800. Consequently, it may reasonably be assumed that
the social makeup of each area is relatively homogeneous, with
few instances of sizeable ‘deprived’ enclaves in afﬂuent areas, and
vice versa. Thus, the characteristics of the area should generally
provide a reliable representation of individual circumstances. It
merits highlighting that there is a very strong tradition of using
SIMD to portray individual SES in health-related research per-
formed in Scotland. Moreover, there is a growing body of inter-
national literature reporting the use of area-based measures to
assess inequalities in health and mortality.27 A third limitation of
the study is that we have not attempted to classify the severity of
the patient’s diabetes at the point of diagnosis. This is a poten-
tially serious weakness, in that poor control and the presence of
complications of diabetes would be expected to exhibit a stronger
association with mortality than less serious manifestations of the
disease. It cannot be discounted that severity of T2DM at presen-
tation may vary by SES, reﬂecting socially patterned differences
in healthcare-seeking behaviour. A fourth limitation is that
because all measures of comorbidity were based on the patient’s
experience prior to the diagnosis of T2DM, no account is taken
of the effect on mortality of complications of diabetes recorded
subsequent to diagnosis (notably macrovascular disease, which is
the main contributor to the excess mortality in people with dia-
betes).1 Another potentially important prognostic factor not
taken into account is smoking behaviour. The prevalence of
smoking is known to vary by SES, and previous research has indi-
cated that both current and former smoking is associated with
increased mortality in diabetic cohorts.28–30
Despite its limitations, this study suggests that the frequently
observed phenomenon of SES-related mortality in people with
diabetes is not wholly explained by a greater burden of disease
in more deprived subgroups. However, the study was conducted
in a Scottish population with T2DM, and this conclusion will
not necessarily hold in other populations. Further research is
required to determine the mechanisms via which the risk of
death in people with diabetes, as in many other populations, is
linked to SES. Of particular interest is the question of whether
these mechanisms—whatever they may be—differ between
people with diabetes and the general population, and whether it
is possible to address these factors in order to reduce health
inequalities.
What is already known on this subject
Mortality in people with diabetes—as in many other
populations—is socially patterned, all-cause mortality risk being
raised in more deprived groups.
What this study adds
▸ Socially patterned mortality in a population with type 2
diabetes is not explained by differential comorbidity
(ie, greater overall burden of disease in deprived groups).
▸ This applies irrespective of how comorbidity is measured.
▸ Further research is needed to clarify how mortality in
populations with diabetes is linked to deprivation.
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